Share on StockTwits
 

Cara Therapeutics (NASDAQ:CARA) major shareholder Ventures Vi Lp Rho bought 225,818 shares of the company’s stock on the open market in a transaction that occurred on Wednesday, February 5th. The stock was purchased at an average cost of $11.00 per share, with a total value of $2,483,998.00. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Cara Therapeutics (NASDAQ:CARA) traded down 9.71% during mid-day trading on Wednesday, hitting $10.60. The stock had a trading volume of 217,239 shares. The stock’s 50-day moving average is $0. and its 200-day moving average is $0.. The company’s market cap is $45.5 million.

Cara Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing new chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.